Board of Directors

Dr Mark Pykett is Chief Executive Officer of Myrtelle, Inc., a private biotechnology company.  He has over 25 years of pharmaceutical industry executive management experience.  Prior to Myrtelle, Dr. Pykett was Chief Scientific Officer at PTC Therapeutics, CEO of Agilis Biotherapeutics, CEO of Navidea Pharmaceuticals, President and Chief Operating Officer of Alseres Pharmaceuticals, President of CyGenics and CEO of Cytomatrix.  He has also been a board member of both public and private organizations, including the biotech companies Pharming Group and Exubrion Therapeutics and the not-for-profit organization HealthBuilders developing healthcare infrastructure in Rwanda.  Dr. Pykett holds a BA from Amherst College, a VMD and PhD from the University of Pennsylvania, and an MBA from Northeastern University.  He also completed post-doctoral work at the University of Pennsylvania and Harvard University. Mark joined the Board of Directors of InFlectis BioScience in October 2021 as Chairman of the Board.

Dr Philippe Guédat has over 20 years of experience in drug discovery in the industry. Philippe held different positions of responsibility in different “business units”. He was the Director of Chemistry at Hybrigenics and the head of the drug discovery department at Vivalis (now Valneva). His expertise ranges from the discovery of chemical molecules with the implementation of high-throughput screening platforms to clinical development of drug candidates. Philippe has a Master’s degree in medicinal chemistry and pharmacology, a Master’s degree of supramolecular organic chemistry and a PhD in medicinal chemistry and pharmacology from the University Louis Pasteur (Strasbourg). Philippe worked at the University of Cambridge (UK), SmithKline Beecham (UK), Merck-Serono, Hybrigenics and Vivalis (now Valneva). In 2013, he founded InFlectis BioScience where is acting as President and Chief Executive Officer since inception.

Jérôme Guéret has a deep experience in venture capital industry and financing. Since 2013, Jérôme is partner at GO Capital, one of the leading high tech venture capital firms in France. Before joining GO Capital, Jérôme was CEO of a high tech electronic company sold to EDF-EN Group in 2008 and was former television VP marketing at Orange Group in 2003. He managed projects and drove strategic execution on new business lines and emerging markets, specifically in telecom and energy sectors. Jerome has a degree from Kedge Business School and an Executive MBA from ESCP Europe.

Taro Inaba is co-Founder and Managing Partner of Remiges Ventures. He has over 27 years of business development and venture investment experience. Currently he holds positions as a board member at Inflectis Bioscience, Omeicos Ophthalmics, Mitoconix Bio, Digestome Therapeutics and Aqross Therapeutics. Prior to establishing Remiges in 2014, he spent 23 years at Mitsui & Co where he spent the last 13 years being engaged in investment activities including a position as President & CEO at Mitsui & Co Venture Partners in Menlo Park from 2008 to 2009. While he was at Mitsui, he holds positions as a board member in 11 companies including Actimis Pharmaceuticals, Boston Biomedical and Hutchison Meidppharma. Taro is co-Founder of Koinobori a philanthropic entity focusing on mitochondrial disease. Taro holds a B.E. in Polymer Chemistry, Kyoto University and MBA from European University. He is a CFA charter holder.